The Rising Cost of Specialty Drugs: 3 Ways Your Medical Practice Can Adapt

Consider a common scenario: a longtime patient comes in for a follow-up, frustrated and exhausted. They've spent weeks battling with their insurance company over their specialty medication - only to be told it isn't covered. The out-of-pocket cost? Almost $4,000 per month. They look at you, their trusted provider, and ask:

"What am I supposed to do now?"

Rising specialty drug costs aren't just putting financial strain on patients; they're disrupting medical practices, overloading staff, and making it harder to deliver high-quality care.

If you own a medical practice, these cost increases are more than just an economic trend - they're an operational challenge that affects patient adherence, administrative workloads, and even your bottom line. Every prior authorization battle, every denied claim, every patient who delays or abandons treatment - these factors add up, creating financial risk and inefficiencies in your practice.

You can't control pharmaceutical pricing. But you can control how your practice navigates these rising costs.

How Specialty Drug Costs Are Disrupting Independent Practices

Rising specialty drug prices don't just affect patients - they create significant operational challenges for medical practices. Administrative workloads have ballooned, reimbursement policies have become more restrictive, and insurers are shifting more financial risk onto providers. These factors make it harder for independent practices to maintain efficiency and profitability while ensuring patients receive timely care.

Administrative Workload: The Prior Authorization Nightmare

Prior authorizations have become one of the biggest obstacles to delivering specialty drug treatments. As insurers tighten approval requirements, providers and staff spend more time navigating the complex, often frustrating PA process than ever.

How Prior Authorizations Are Draining Your Staff's Time

Physician surveys have consistently found that prior authorization consumes a substantial share of each physician's week, and that burden compounds across a practice - every additional prescriber adds another queue of pending requests for the same support staff to work. Specialty drugs, in particular, require multiple rounds of approval, adding further complexity to an already time-consuming process. The only number that matters for planning purposes is your own: track PA hours for a month before assuming a published figure describes your practice.

Practices that administer biologics, infusions, or other high-cost specialty medications in-office face an even greater challenge. Insurers frequently demand step therapy protocols, requiring patients to "fail" on less expensive treatments before approving the specialty drug. In other cases, restrictive formularies force providers to resubmit documentation every few months - even when a patient has been stable on a medication for years.

The Hidden Impact on Patient Care

While PA requirements are intended to control costs, they often create dangerous delays in treatment. Patients waiting for insurer approval may go weeks or months without access to their prescribed medication. Clinicians widely report that such gaps can contribute to worsening symptoms, disease progression, and avoidable hospitalizations, though the degree of harm varies by condition and by how long the delay runs.

Many patients become so discouraged by the process that they give up entirely. Physician and pharmacy surveys have repeatedly linked burdensome prior authorization requirements to prescription abandonment, and that pattern is one of the more consistent findings in the literature on access barriers.

Administrative Burden and Burnout: A Growing Crisis

Beyond patient care, PA inefficiencies heavily impact your practice's workflow. The constant need to follow up on approvals, correct denied claims, and navigate insurance appeals adds to staff burnout. Medical assistants, nurses, and administrative teams are stretched thin, forced to juggle patient care with endless insurance battles.

This workload is even harder to manage for independent practices without large administrative teams. Many small practices cannot afford to dedicate staff solely to handling PAs, leading to longer wait times, lower patient satisfaction, and growing frustration among providers and staff alike.

If prior authorization hurdles continue at this pace, independent practices, especially those without dedicated administrative support teams, will struggle to keep up.

How Your Practice Can Adapt and Stay Ahead

While you can't change the rising cost of specialty drugs, you can proactively protect your practice, streamline operations, and support your patients. Here's how:

1) Reduce Administrative Burden by Streamlining Prior Authorizations

One of the most effective ways to ease the burden on your practice is by implementing systems that speed up prior authorization approvals. If your staff is drowning in paperwork, it's time to optimize the process.

Use Electronic Prior Authorization (ePA) Systems to Cut Processing Time

Many practices now use electronic prior authorization (ePA) systems, including platforms such as CoverMyMeds and Surescripts. Instead of spending hours on the phone with insurers, these platforms handle real-time authorization requests, flag missing documentation, and reduce delays. Vendors publish their own time-savings figures; treat those as marketing claims to be evaluated against your own measured baseline rather than as a guaranteed result, and ask for references from practices with a similar payer mix.

Assign a Prior Authorization Specialist to Improve Efficiency

If your practice handles a high volume of specialty medications, consider designating a PA specialist - someone on your team dedicated solely to managing authorization requests. This can reduce disruptions in patient care and improve consistency in how approvals are handled.

Track PA Trends and Use Data to Negotiate with Payers

Tracking prior authorization trends can also be a powerful tool. If certain insurers or medications are repeatedly getting denied, document these patterns and bring them to payer contract negotiations. Sometimes, simply presenting data on how PA delays impact patient outcomes can push insurers to adjust their policies.

2) Strengthen Your Practice's Financial Position Through Smarter Payer Negotiations

Independent practices often feel powerless in the face of insurance policies - but negotiation is possible, especially if you come to the table with data.

If you administer specialty drugs in-office, clarify your reimbursement structure with payers. ASP (Average Sales Price) plus 6 percent is the statutory Medicare Part B rate for most separately payable Part B drugs, not a commercial standard - and sequestration reduces the effective payment below the nominal ASP+6. Commercial payers set their own methodologies, which may be benchmarked to ASP, to a percentage of AWP, or to a flat fee per administration. Pull your actual contracts and confirm the methodology, the benchmark source, and the update frequency rather than assuming any of them. If you're losing money on drug reimbursement delays, push for more transparent and predictable payment models.

Another key negotiation point? Formulary flexibility. If your practice sees consistent denials for a certain specialty drug, you may be able to negotiate lower PA requirements for that medication - especially if you can demonstrate that denials are leading to higher long-term healthcare costs for the insurer.

The key to successful payer negotiations is data. Track how much time your staff spends on denials, how many patients face treatment interruptions, and how many appeals are required per medication. The more quantifiable evidence you can provide, the stronger your negotiating position.

3) Help Patients Access Affordable Specialty Medications

Your patients rely on you for medical care and look to you for guidance in navigating the confusing world of drug pricing. You can improve adherence, retention, and outcomes by proactively connecting patients with financial assistance programs.

Many pharmaceutical manufacturers offer copay assistance programs, but patients often don't know these exist. Consider having a dedicated staff member or resource guide available to help patients find:

• Manufacturer patient assistance programs (PAPs), which typically serve uninsured or underinsured patients against income criteria
• Manufacturer copay cards, which reduce cost-sharing for commercially insured patients
• State and nonprofit drug cost relief programs
• Independent charitable foundations that cover specialty drug expenses

Before you build any referral workflow, understand that these three categories operate under different rules. Manufacturer copay cards are generally not available to patients enrolled in Medicare, Medicaid, TRICARE, or other federal healthcare programs, and steering federal beneficiaries toward assistance - or routing them to a particular product or foundation - can create exposure under the Anti-Kickback Statute and the beneficiary inducement provisions of the Civil Monetary Penalties Law. Independent charitable foundations may serve federal beneficiaries, but only where the foundation is genuinely independent of any manufacturer and operates within the parameters OIG has described in its advisory opinions and bulletins on patient assistance. Manufacturer PAPs sit somewhere in between and vary program by program.

Confirm each program's eligibility rules and your own compliance posture with counsel before you formalize how staff present these options to patients. A well-intentioned workflow that treats all three categories as interchangeable is the version that creates risk.

A note on 340B. 340B drug pricing is sometimes raised in this conversation, and it is frequently misunderstood. A private practice cannot become 340B-eligible by partnering with an FQHC or a hospital. Eligibility attaches only to the covered entity types listed in the statute - FQHCs and look-alikes, disproportionate share hospitals, Ryan White clinics, and the other specified grantee categories. A practice can dispense or administer 340B-purchased drugs only if it is formally registered as a child site of a covered entity in HRSA's Office of Pharmacy Affairs database, or is operating as a contracted provider within that entity's scope of project - and in either case the covered entity retains responsibility for patient eligibility determinations, auditable records, and diversion prevention. Purchasing 340B drugs outside that structure is diversion. If this is a direction you are considering, start with HRSA's Office of Pharmacy Affairs and 340B counsel, not with a handshake arrangement.

The more financial resources you provide, the better your patients' chances of staying on therapy - and staying with your practice.

Final Thoughts: How Independent Practices Can Take Control

The rising cost of specialty drugs isn't just a pharmaceutical industry issue - it's a day-to-day operational challenge for independent medical practices.

The key to protecting your practice and supporting your patients lies in:

• Optimizing prior authorization workflows to reduce administrative waste
• Negotiating smarter with payers to secure better reimbursement terms
• Helping patients access financial assistance to improve adherence

Specialty drug prices may continue to rise, but your practice doesn't have to absorb the full impact. Acting deliberately on these three fronts can strengthen your practice's financial position while you continue delivering high-quality care to your patients.

Remy Healthcare helps practices navigate the financial and administrative challenges of specialty drug costs. From streamlining prior authorizations to improving payer negotiations, we provide the solutions you need to protect your bottom line and keep patients on therapy. Get in touch with our team today to learn how we can support your practice!